All the latest packaging trends for life sciences, all at PACK EXPO East
Explore new packaging solutions for life sciences, all in one convenient location at PACK EXPO East, March 18 – 20 in Philadelphia.

FDA approves blood clot prevention drug after multiple setbacks

The company has reportedly spent $200 million over a decade seeking approval

After a decade-long battle, the FDA approved blood clot preventer Cangrelor by Medicines Co's.

Also known as Kengreal, it is an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries, the blood vessels that supply blood to the heart.

It is approved for adult patients undergoing percutaneous coronary intervention (PCI), a procedure used to open a blocked or narrowed coronary artery to improve blood flow to the heart muscle.

By preventing platelets from accumulating, Kengreal reduces the risk of serious clotting complications related to the procedure, including heart attack and clotting of the stent, the FDA explained.

According to Reuters, Medicines Co has spend $200 million developing the drug, including two trials that were unsuccessful.

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub
Discover the right packaging solutions for life sciences in Philadelphia
Explore innovative packaging and supply chain solutions for the life sciences at the largest PACK EXPO East in history, March 18–20. Get ideas from 400+ top exhibitors and connect with colleagues and industry experts—all in one convenient location!
Read More
Discover the right packaging solutions for life sciences in Philadelphia